In subsets of patients with ovarian cancer and other tumor types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor growth. However, prior drug discovery efforts targeting CDK2 have been hindered by challenges in achieving selectivity over other CDK family members associated with toxicity.ĬDK2 is believed to play an important role in tumor proliferation for patients with HR-positive, HER2-negative metastatic breast cancer. CDK2 and CCNE1 are central to regulating the cell cycle, which is involved in the process of cell growth and division. View clinical trials of avapritinib.īLU-222 is a potent and selective CDK2 inhibitor for the treatment of patients with CDK2-vulnerable cancers, including hormone receptor (HR)-positive, HER2-negative breast cancer and CCNE1 aberrant tumors. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing. Food and Drug Administration (FDA) for the treatment of moderate to severe indolent SM.īlueprint Medicines is developing avapritinib as a potential treatment for a broad population of patients with SM globally, including advanced and non-advanced SM.
– A minority of patients have advanced SM in addition to mast cell activation symptoms, it is associated with organ damage due to mast cell infiltration and poor overall survival.Īvapritinib has received breakthrough therapy designation from the U.S. – The vast majority of those affected have non-advanced (indolent or smoldering) SM, with debilitating symptoms that lead to a profound, negative impact on quality of life. SM comprises a disease spectrum ranging from indolent SM, which is predominantly characterized by severe constitutional symptoms caused by mast cell degranulation and mediator release, to advanced SM, which is characterized by organ dysfunction and reduced survival due to mast cell infiltration.
#Blueprint medicines driver#
If you have any questions, please contact customer support at 1-888-BLUPRNT (1-88).Systemic mastocytosis (SM) is a rare disease that results from the abnormal proliferation of mast cells across all forms of SM, the KIT D816V mutation is the primary driver of disease. Offer is not valid if the patient is uninsured or paying cash for the prescription. Blueprint Medicines reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice. Applying an approach that is both precise and agile. That’s why we offer a range of personalized services to help you get onand stay onyour prescribed treatment. Call us today 1-888-BLUPRNT (1-88) Every person is unique. Offer is not available to patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, such as patients enrolled in Medicare Part D and patients whose prescription is paid for by Medicare, Medicaid, Medigap, CHAMPUS, Department of Defense (DoD), TRICARE, Veterans Affairs (VA), Children’s Heath Insurance Program (CHIP), the Indian Health Service, or a state pharmaceutical assistance program. Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and blood disorders. This is YourBlueprint We offer personalized services right from the start of your prescribed Blueprint Medicines therapy.
You will enter a website that is not owned or controlled by Blueprint Medicines. This program may not be combined with any third-party rebate, coupon, or offer. You are about to leave the YourBlueprint website. Program is not valid where prohibited by law. Patient is responsible for complying with any applicable limitations and requirements of his/her health plan related to the use of the program. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. The value of this program is exclusively for the benefit of enrolled patients and is intended to be credited toward patient out-of-pocket obligations, including applicable co-payments, co-insurance, and deductibles. Blueprint Medicines Global Headquarters 45 Sidney Street Cambridge, MA 02139 (617) 374-7580.
0 kommentar(er)
